View Item 

Show simple item record

Twice‐weekly ixazomib in combination with lenalidomide‐dexamethasone in patients with newly diagnosed multiple myeloma
dc.contributor.authorRichardson, Paul G.
dc.contributor.authorHofmeister, Craig C.
dc.contributor.authorRosenbaum, Cara A.
dc.contributor.authorHtut, Myo
dc.contributor.authorVesole, David H.
dc.contributor.authorBerdeja, Jesus G.
dc.contributor.authorLiedtke, Michaela
dc.contributor.authorChari, Ajai
dc.contributor.authorSmith, Stephen D.
dc.contributor.authorLebovic, Daniel
dc.contributor.authorRaje, Noopur
dc.contributor.authorByrne, Catriona
dc.contributor.authorLiao, Eileen
dc.contributor.authorGupta, Neeraj
dc.contributor.authorBacco, Alessandra Di
dc.contributor.authorEstevam, Jose
dc.contributor.authorBerg, Deborah
dc.contributor.authorBaz, Rachid
dc.date.accessioned2018-07-13T15:47:50Z
dc.date.available2019-09-04T20:15:39Zen
dc.date.issued2018-07
dc.identifier.citationRichardson, Paul G.; Hofmeister, Craig C.; Rosenbaum, Cara A.; Htut, Myo; Vesole, David H.; Berdeja, Jesus G.; Liedtke, Michaela; Chari, Ajai; Smith, Stephen D.; Lebovic, Daniel; Raje, Noopur; Byrne, Catriona; Liao, Eileen; Gupta, Neeraj; Bacco, Alessandra Di; Estevam, Jose; Berg, Deborah; Baz, Rachid (2018). "Twice‐weekly ixazomib in combination with lenalidomide‐dexamethasone in patients with newly diagnosed multiple myeloma." British Journal of Haematology 182(2): 231-244.
dc.identifier.issn0007-1048
dc.identifier.issn1365-2141
dc.identifier.urihttps://hdl.handle.net/2027.42/144661
dc.publisherWiley Periodicals, Inc.
dc.subject.otherixazomib
dc.subject.otheroral
dc.subject.othernewly diagnosed
dc.subject.othermultiple myeloma
dc.subject.othertwice‐weekly
dc.titleTwice‐weekly ixazomib in combination with lenalidomide‐dexamethasone in patients with newly diagnosed multiple myeloma
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/144661/1/bjh15394.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/144661/2/bjh15394_am.pdf
dc.identifier.doi10.1111/bjh.15394
dc.identifier.sourceBritish Journal of Haematology
dc.identifier.citedreferenceKumar, S.K., Berdeja, J.G.B., Niesvizky, R., Lonial, S., Laubach, J.P.H., Hamadani, M., Stewart, A.K., Hari, P.H., Roy, V., Vescio, R., Kaufman, J.L., Berg, D., Liao, E., Hui, A.M., Rajkumar, S.V. & Richardson, P.G. ( 2014c ) Long‐term ixazomib maintenance is tolerable and improves depth of response following ixazomib‐lenalidomide‐dexamethasone induction in patients (Pts) with previously untreated multiple myeloma (MM): phase 2 study results. Blood, 124, 82.
dc.identifier.citedreferenceDurie, B.G., Hoering, A., Abidi, M.H., Rajkumar, S.V., Epstein, J., Kahanic, S.P., Thakuri, M., Reu, F., Reynolds, C.M., Sexton, R., Orlowski, R.Z., Barlogie, B. & Dispenzieri, A. ( 2017 ) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem‐cell transplant (SWOG S0777): a randomised, open‐label, phase 3 trial. Lancet, 389, 519 – 527.
dc.identifier.citedreferenceDytfeld, D., Jasielec, J., Griffith, K.A., Lebovic, D., Vesole, D.H., Jagannath, S., Al‐Zoubi, A., Anderson, T., Detweiler‐Short, K., Stockerl‐Goldstein, K., Ahmed, A., Jobkar, T., Durecki, D.E., McDonnell, K., Mietzel, M., Couriel, D., Kaminski, M., Vij, R. & Jakubowiak, A.J. ( 2014 ) Carfilzomib, lenalidomide, and low‐dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. Haematologica, 99, e162 – e164.
dc.identifier.citedreferenceGarderet, L., Iacobelli, S., Moreau, P., Dib, M., Lafon, I., Niederwieser, D., Masszi, T., Fontan, J., Michallet, M., Gratwohl, A., Milone, G., Doyen, C., Pegourie, B., Hajek, R., Casassus, P., Kolb, B., Chaleteix, C., Hertenstein, B., Onida, F., Ludwig, H., Ketterer, N., Koenecke, C., van Os, M., Mohty, M., Cakana, A., Gorin, N.C., de Witte, T., Harousseau, J.L., Morris, C. & Gahrton, G. ( 2012 ) Superiority of the triple combination of bortezomib‐thalidomide‐dexamethasone over the dual combination of thalidomide‐dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005‐04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 30, 2475 – 2482.
dc.identifier.citedreferenceGuglielmelli, T. & Palumbo, A. ( 2015 ) Multiple myeloma: is a shift toward continuous therapy needed to move forward? Expert Review of Hematology, 8, 253 – 256.
dc.identifier.citedreferenceGupta, N., Zhao, Y., Hui, A.M., Esseltine, D.L. & Venkatakrishnan, K. ( 2015a ) Switching from body surface area‐based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis. British Journal of Clinical Pharmacology, 79, 789 – 800.
dc.identifier.citedreferenceGupta, N., Huh, Y., Hutmacher, M.M., Ottinger, S., Hui, A.M. & Venkatakrishnan, K. ( 2015b ) Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients. Cancer Chemotherapy and Pharmacology, 76, 507 – 516.
dc.identifier.citedreferenceGupta, N., Hanley, M.J., Venkatakrishnan, K., Wang, B., Sharma, S., Bessudo, A., Hui, A.M. & Nemunaitis, J. ( 2016a ) The effect of a high‐fat meal on the pharmacokinetics of ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors or lymphoma. Journal of Clinical Pharmacology, 56, 1288 – 1295.
dc.identifier.citedreferenceGupta, N., Labotka, R., Liu, G., Hui, A.M. & Venkatakrishnan, K. ( 2016b ) Exposure‐safety‐efficacy analysis of single‐agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study. Investigational New Drugs, 34, 338 – 346.
dc.identifier.citedreferenceGupta, N., Diderichsen, P.M., Hanley, M.J., Berg, D., van de Velde, H., Harvey, R.D. & Venkatakrishnan, K. ( 2017a ) Population pharmacokinetic analysis of ixazomib, an oral proteasome inhibitor, including data from the phase III TOURMALINE‐MM1 study to inform labelling. Clinical Pharmacokinetics, 56, 1355 – 1368.
dc.identifier.citedreferenceGupta, N., Yang, H., Hanley, M.J., Zhang, S., Liu, R., Kumar, S., Richardson, P.G., Skacel, T. & Venkatakrishnan, K. ( 2017b ) Dose and schedule selection of the oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma: clinical and model‐based analyses. Target Oncology, 12, 643 – 654.
dc.identifier.citedreferenceJakubowiak, A.J., Dytfeld, D., Griffith, K.A., Lebovic, D., Vesole, D.H., Jagannath, S., Al‐Zoubi, A., Anderson, T., Nordgren, B., Detweiler‐Short, K., Stockerl‐Goldstein, K., Ahmed, A., Jobkar, T., Durecki, D.E., McDonnell, K., Mietzel, M., Couriel, D., Kaminski, M. & Vij, R. ( 2012 ) A phase 1/2 study of carfilzomib in combination with lenalidomide and low‐dose dexamethasone as a frontline treatment for multiple myeloma. Blood, 120, 1801 – 1809.
dc.identifier.citedreferenceKatodritou, E., Papadaki, S., Konstantinidou, P. & Terpos, E. ( 2016 ) Is it possible to cure myeloma without allogeneic transplantation? Transfusion and Apheresis Science, 54, 63 – 70.
dc.identifier.citedreferenceKorde, N., Roschewski, M., Zingone, A., Kwok, M., Manasanch, E.E., Bhutani, M., Tageja, N., Kazandjian, D., Mailankody, S., Wu, P., Morrison, C., Costello, R., Zhang, Y., Burton, D., Mulquin, M., Zuchlinski, D., Lamping, L., Carpenter, A., Wall, Y., Carter, G., Cunningham, S.C., Gounden, V., Sissung, T.M., Peer, C., Maric, I., Calvo, K.R., Braylan, R., Yuan, C., Stetler‐Stevenson, M., Arthur, D.C., Kong, K.A., Weng, L., Faham, M., Lindenberg, L., Kurdziel, K., Choyke, P., Steinberg, S.M., Figg, W. & Landgren, O. ( 2015 ) Treatment with carfilzomib‐lenalidomide‐dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncology, 1, 746 – 754.
dc.identifier.citedreferenceKoulaouzidis, G. & Lyon, A.R. ( 2017 ) Proteasome inhibitors as a potential cause of heart failure. Heart Failure Clinics, 13, 289 – 295.
dc.identifier.citedreferenceKumar, S.K., Rajkumar, S.V., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Zeldenrust, S.R., Dingli, D., Russell, S.J., Lust, J.A., Greipp, P.R., Kyle, R.A. & Gertz, M.A. ( 2008 ) Improved survival in multiple myeloma and the impact of novel therapies. Blood, 111, 2516 – 2520.
dc.identifier.citedreferenceKumar, S., Flinn, I., Richardson, P.G., Hari, P., Callander, N., Noga, S.J., Stewart, A.K., Turturro, F., Rifkin, R., Wolf, J., Estevam, J., Mulligan, G., Shi, H., Webb, I.J. & Rajkumar, S.V. ( 2012 ) Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood, 119, 4375 – 4382.
dc.identifier.citedreferenceKumar, S.K., Dispenzieri, A., Lacy, M.Q., Gertz, M.A., Buadi, F.K., Pandey, S., Kapoor, P., Dingli, D., Hayman, S.R., Leung, N., Lust, J., McCurdy, A., Russell, S.J., Zeldenrust, S.R., Kyle, R.A. & Rajkumar, S.V. ( 2014a ) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia, 28, 1122 – 1128.
dc.identifier.citedreferenceKumar, S.K., Berdeja, J.G., Niesvizky, R., Lonial, S., Laubach, J.P., Hamadani, M., Stewart, A.K., Hari, P., Roy, V., Vescio, R., Kaufman, J.L., Berg, D., Liao, E., Di Bacco, A., Estevam, J., Gupta, N., Hui, A.M., Rajkumar, V. & Richardson, P.G. ( 2014b ) Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open‐label phase 1/2 study. Lancet Oncology, 15, 1503 – 1512.
dc.identifier.citedreferenceKumar, S.K., Bensinger, W.I., Zimmerman, T.M., Reeder, C.B., Berenson, J.R., Berg, D., Hui, A.M., Gupta, N., Di Bacco, A., Yu, J., Shou, Y. & Niesvizky, R. ( 2014d ) Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood, 124, 1047 – 1055.
dc.identifier.citedreferenceKumar, S.K., Callander, N.S., Alsina, M., Atanackovic, D., Biermann, J.S., Chandler, J.C., Costello, C., Faiman, M., Fung, H.C., Gasparetto, C., Godby, K., Hofmeister, C., Holmberg, L., Holstein, S., Huff, C.A., Kassim, A., Liedtke, M., Martin, T., Omel, J., Raje, N., Reu, F.J., Singhal, S., Somlo, G., Stockerl‐Goldstein, K., Treon, S.P., Weber, D., Yahalom, J., Shead, D.A. & Kumar, R. ( 2017 ) Multiple myeloma, Version 3.2017, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 15, 230 – 269.
dc.identifier.citedreferenceTinsley, S.M., Kurtin, S.E. & Ridgeway, J.A. ( 2015 ) Practical management of lenalidomide‐related rash. Clinical Lymphoma, Myeloma and Leukemia, 15, S64 – S69.
dc.identifier.citedreferenceLudwig, H., Greil, R., Masszi, T., Spicka, I., Shpilberg, O., Hajek, R., Dmoszynska, A., Paiva, B., Vidriales, M.B., Esteves, G., Stoppa, A.M., Robinson, D. Jr, Chaturvedi, S., Ataman, O., Enny, C., Feng, H., van de Velde, H. & Viterbo, L. ( 2015 ) Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up. British Journal of Haematology, 171, 344 – 354.
dc.identifier.citedreferenceMateos, M.V., Oriol, A., Martinez‐Lopez, J., Gutierrez, N., Teruel, A.I., Lopez de la Guia, A., Lopez, J., Bengoechea, E., Perez, M., Polo, M., Palomera, L., de Arriba, F., Gonzalez, Y., Hernandez, J.M., Granell, M., Bello, J.L., Bargay, J., Penalver, F.J., Ribera, J.M., Martin‐Mateos, M.L., Garcia‐Sanz, R., Lahuerta, J.J., Blade, J. & San‐Miguel, J.F. ( 2012 ) Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood, 120, 2581 – 2588.
dc.identifier.citedreferenceMoreau, P., Masszi, T., Grzasko, N., Bahlis, N.J., Hansson, M., Pour, L., Sandhu, I., Ganly, P., Baker, B.W., Jackson, S.R., Stoppa, A.M., Simpson, D.R., Gimsing, P., Palumbo, A., Garderet, L., Cavo, M., Kumar, S., Touzeau, C., Buadi, F.K., Laubach, J.P., Berg, D.T., Lin, J., Di Bacco, A., Hui, A.M., van de Velde, H., Richardson, P.G. & TOURMALINE‐MM1 Study Group. ( 2016 ) Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. New England Journal of Medicine, 374, 1621 – 1634.
dc.identifier.citedreferencePalumbo, A., Bringhen, S., Rossi, D., Cavalli, M., Larocca, A., Ria, R., Offidani, M., Patriarca, F., Nozzoli, C., Guglielmelli, T., Benevolo, G., Callea, V., Baldini, L., Morabito, F., Grasso, M., Leonardi, G., Rizzo, M., Falcone, A.P., Gottardi, D., Montefusco, V., Musto, P., Petrucci, M.T., Ciccone, G. & Boccadoro, M. ( 2010 ) Bortezomib‐melphalan‐prednisone‐thalidomide followed by maintenance with bortezomib‐thalidomide compared with bortezomib‐melphalan‐prednisone for initial treatment of multiple myeloma: a randomized controlled trial. Journal of Clinical Oncology, 28, 5101 – 5109.
dc.identifier.citedreferencePalumbo, A., Cavallo, F., Gay, F., Di Raimondo, F., Ben Yehuda, D., Petrucci, M.T., Pezzatti, S., Caravita, T., Cerrato, C., Ribakovsky, E., Genuardi, M., Cafro, A., Marcatti, M., Catalano, L., Offidani, M., Carella, A.M., Zamagni, E., Patriarca, F., Musto, P., Evangelista, A., Ciccone, G., Omede, P., Crippa, C., Corradini, P., Nagler, A., Boccadoro, M. & Cavo, M. ( 2014 ) Autologous transplantation and maintenance therapy in multiple myeloma. New England Journal of Medicine, 371, 895 – 905.
dc.identifier.citedreferencePalumbo, A., Gay, F., Cavallo, F., Di Raimondo, F., Larocca, A., Hardan, I., Nagler, A., Petrucci, M.T., Hajek, R., Pezzatti, S., Delforge, M., Patriarca, F., Donato, F., Cerrato, C., Nozzoli, C., Yu, Z., Boccadifuoco, L., Caravita, T., Benevolo, G., Guglielmelli, T., Vincelli, D., Jacques, C., Dimopoulos, M.A., Ciccone, G., Musto, P., Corradini, P., Cavo, M. & Boccadoro, M. ( 2015 ) Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma. Journal of Clinical Oncology, 33, 3459 – 3466.
dc.identifier.citedreferencePulte, D., Gondos, A. & Brenner, H. ( 2011 ) Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data. Oncologist, 16, 1600 – 1603.
dc.identifier.citedreferenceRajkumar, S.V., Harousseau, J.L., Durie, B., Anderson, K.C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., Jagannath, S., Facon, T., Avet‐Loiseau, H., Lonial, S., Palumbo, A., Zonder, J., Ludwig, H., Vesole, D., Sezer, O., Munshi, N.C. & San Miguel, J. for the International Myeloma Workshop Consensus Panel. ( 2011 ) Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood, 117, 4691 – 4695.
dc.identifier.citedreferenceRichardson, P.G., Weller, E., Lonial, S., Jakubowiak, A.J., Jagannath, S., Raje, N.S., Avigan, D.E., Xie, W., Ghobrial, I.M., Schlossman, R.L., Mazumder, A., Munshi, N.C., Vesole, D.H., Joyce, R., Kaufman, J.L., Doss, D., Warren, D.L., Lunde, L.E., Kaster, S., Delaney, C., Hideshima, T., Mitsiades, C.S., Knight, R., Esseltine, D.L. & Anderson, K.C. ( 2010 ) Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood, 116, 679 – 686.
dc.identifier.citedreferenceRichardson, P.G., Baz, R., Wang, M., Jakubowiak, A.J., Laubach, J.P., Harvey, R.D., Talpaz, M., Berg, D., Liu, G., Yu, J., Gupta, N., Di Bacco, A., Hui, A.M. & Lonial, S. ( 2014 ) Phase 1 study of twice‐weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood, 124, 1038 – 1046.
dc.identifier.citedreferenceRosinol, L., Oriol, A., Teruel, A.I., Hernandez, D., Lopez‐Jimenez, J., de la Rubia, J., Granell, M., Besalduch, J., Palomera, L., Gonzalez, Y., Etxebeste, M.A., Diaz‐Mediavilla, J., Hernandez, M.T., de Arriba, F., Gutierrez, N.C., Martin‐Ramos, M.L., Cibeira, M.T., Mateos, M.V., Martinez, J., Alegre, A., Lahuerta, J.J., San Miguel, J. & Blade, J. ( 2012 ) Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood, 120, 1589 – 1596.
dc.identifier.citedreferenceRoussel, M., Lauwers‐Cances, V., Robillard, N., Belhadj, K., Facon, T., Garderet, L., Escoffre, M., Pegourie, B., Benboubker, L., Caillot, D., Fohrer, C., Moreau, P., Leleu, X., Avet‐Loiseau, H. & Attal, M. ( 2016 ) Frontline therapy with carfilzomib, lenalidomide, and dexamethasone (KRd) induction followed by autologous stem cell transplantation, Krd consolidation and lenalidomide maintenance in newly diagnosed multiple myeloma (NDMM) patients: primary results of the intergroupe francophone du myélome (IFM) Krd Phase II Study. Blood, 128, 1142.
dc.identifier.citedreferenceStewart, A.K., Rajkumar, S.V., Dimopoulos, M.A., Masszi, T., Spicka, I., Oriol, A., Hajek, R., Rosinol, L., Siegel, D.S., Mihaylov, G.G., Goranova‐Marinova, V., Rajnics, P., Suvorov, A., Niesvizky, R., Jakubowiak, A.J., San‐Miguel, J.F., Ludwig, H., Wang, M., Maisnar, V., Minarik, J., Bensinger, W.I., Mateos, M.V., Ben‐Yehuda, D., Kukreti, V., Zojwalla, N., Tonda, M.E., Yang, X., Xing, B., Moreau, P., Palumbo, A. & Investigators, A. ( 2015 ) Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. New England Journal of Medicine, 372, 142 – 152.
dc.identifier.citedreferenceAttal, M., Lauwers‐Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A.M., Hulin, C., Benboubker, L., Garderet, L., Decaux, O., Leyvraz, S., Vekemans, M.C., Voillat, L., Michallet, M., Pegourie, B., Dumontet, C., Roussel, M., Leleu, X., Mathiot, C., Payen, C., Avet‐Loiseau, H., Harousseau, J.L. & Investigators, I.F.M. ( 2012 ) Lenalidomide maintenance after stem‐cell transplantation for multiple myeloma. New England Journal of Medicine, 366, 1782 – 1791.
dc.identifier.citedreferenceBarlogie, B., Mitchell, A., van Rhee, F., Epstein, J., Morgan, G.J. & Crowley, J. ( 2014 ) Curing myeloma at last: defining criteria and providing the evidence. Blood, 124, 3043 – 3051.
dc.identifier.citedreferenceBattisti, W.P., Wager, E., Baltzer, L., Bridges, D., Cairns, A., Carswell, C.I., Citrome, L., Gurr, J.A., Mooney, L.A., Moore, B.J., Peña, T., Sanes‐Miller, C.H., Veitch, K., Woolley, K.L. & Yarker, Y.E. & International Society for Medical Publication Professionals. ( 2015 ) Good publication practice for communicating company‐sponsored medical research: GPP3. Annals of Internal Medicine, 163, 461 – 464.
dc.identifier.citedreferenceBaz, R., Lin, H.M., Hui, A.M., Harvey, R.D., Colson, K., Gallop, K., Swinburn, P., Laubach, J., Berg, D. & Richardson, P. ( 2015 ) Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health‐related quality of life. Supportive Care in Cancer, 23, 2789 – 2797.
dc.identifier.citedreferenceBenboubker, L., Dimopoulos, M.A., Dispenzieri, A., Catalano, J., Belch, A.R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., Banos, A., Tiab, M., Delforge, M., Cavenagh, J., Geraldes, C., Lee, J.J., Chen, C., Oriol, A., de la Rubia, J., Qiu, L., White, D.J., Binder, D., Anderson, K., Fermand, J.P., Moreau, P., Attal, M., Knight, R., Chen, G., Van Oostendorp, J., Jacques, C., Ervin‐Haynes, A., Avet‐Loiseau, H., Hulin, C. & Facon, T. ( 2014 ) Lenalidomide and dexamethasone in transplant‐ineligible patients with myeloma. New England Journal of Medicine, 371, 906 – 917.
dc.identifier.citedreferenceCalhoun, E.A., Welshman, E.E., Chang, C.H., Lurain, J.R., Fishman, D.A., Hunt, T.L. & Cella, D. ( 2003 ) Psychometric evaluation of the functional assessment of cancer therapy/gynecologic oncology group‐neurotoxicity (Fact/GOG‐Ntx) questionnaire for patients receiving systemic chemotherapy. International Journal of Gynecological Cancer, 13, 741 – 748.
dc.identifier.citedreferenceCavo, M., Tacchetti, P., Patriarca, F., Petrucci, M.T., Pantani, L., Galli, M., Di Raimondo, F., Crippa, C., Zamagni, E., Palumbo, A., Offidani, M., Corradini, P., Narni, F., Spadano, A., Pescosta, N., Deliliers, G.L., Ledda, A., Cellini, C., Caravita, T., Tosi, P. & Baccarani, M. ( 2010 ) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem‐cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet, 376, 2075 – 2085.
dc.identifier.citedreferenceCavo, M., Pantani, L., Petrucci, M.T., Patriarca, F., Zamagni, E., Donnarumma, D., Crippa, C., Boccadoro, M., Perrone, G., Falcone, A., Nozzoli, C., Zambello, R., Masini, L., Furlan, A., Brioli, A., Derudas, D., Ballanti, S., Dessanti, M.L., De Stefano, V., Carella, A.M., Marcatti, M., Nozza, A., Ferrara, F., Callea, V., Califano, C., Pezzi, A., Baraldi, A., Grasso, M., Musto, P. & Palumbo, A. ( 2012 ) Bortezomib‐thalidomide‐dexamethasone is superior to thalidomide‐dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood, 120, 9 – 19.
dc.identifier.citedreferenceDelforge, M. & Ludwig, H. ( 2017 ) How I manage the toxicities of myeloma drugs. Blood, 129, 2359 – 2367.
dc.identifier.citedreferenceDowling, M., Kelly, M. & Meenaghan, T. ( 2016 ) Multiple myeloma: managing a complex blood cancer. British Journal of Nursing, 25, S18 – S28.
dc.identifier.citedreferenceDurie, B.G., Harousseau, J.L., Miguel, J.S., Blade, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Cavo, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G. & Rajkumar, S.V. & International Myeloma Working Group. ( 2006 ) International uniform response criteria for multiple myeloma. Leukemia, 20, 1467 – 1473.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
bjh15394.pdf
Size:
283.2KB
Format:
PDF
View/Open
Name:
bjh15394_am.pdf
Size:
297.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.